Literature DB >> 35262754

The neurosurgical management of Severe Hemophilia A and Moyamoya (SHAM): challenges, strategies, and literature review.

Risheng Xu1, Anita L Kalluri1, Lisa R Sun1, Courtney E Lawrence1, Jennifer K Lee1, Sujatha Kannan1, Alan R Cohen2.   

Abstract

INTRODUCTION: Severe Hemophilia A and Moyamoya arteriopathy (SHAM syndrome) is a rare genetic disorder caused by deletion of portions of the cytogenic band Xq28. A case of SHAM syndrome requiring bilateral cerebral revascularization is described with an emphasis on perioperative management. CASE REPORT: A 5-year-old boy with severe hemophilia A complicated by factor VIII inhibition presented with right-sided weakness. Imaging revealed multiple strokes and vascular changes consistent with Moyamoya disease. The patient underwent two-staged indirect cerebral bypass revascularizations, first on the left side and several months later on the right. Perioperative management required balancing the administration of agents to prevent coagulopathy and perioperative hemorrhage while mitigating the risk of thromboembolic events associated with bypass surgery. Despite a multidisciplinary effort by the neurosurgery, hematology, critical care, and anesthesiology teams, the post-operative course after both surgeries was complicated by stroke. Fortunately, the patient recovered rapidly to his preoperative functional baseline.
CONCLUSION: We describe a rare case of SHAM syndrome in a pediatric patient who required bilateral revascularizations and discuss strategies for managing the perioperative risk of hemorrhage and stroke. We also review existing literature on SHAM syndrome.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Coagulopathy; Hemophilia; Indirect bypass; Revascularization

Mesh:

Substances:

Year:  2022        PMID: 35262754     DOI: 10.1007/s00381-022-05489-5

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.532


  2 in total

Review 1.  Moyamoya Disease: A Review of Clinical Research.

Authors:  Tomohito Hishikawa; Kenji Sugiu; Isao Date
Journal:  Acta Med Okayama       Date:  2016-08       Impact factor: 0.892

Review 2.  Factor VIII replacement is still the standard of care in haemophilia A.

Authors:  Louis Aledort; Pier Mannuccio Mannucci; Wolfgang Schramm; Michael Tarantino
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.